Showing results (21-30 of 36) with videos related to
Sort By:
Pageof 4
Clinical Therapeutics|July 6, 2019
Effects of a High-fat Meal on the Pharmacokinetics of the VEGFR Inhibitor Fruquintinib: A Randomized Phase I Study in Healthy SubjectsHongjie Qian, Songhua Fan, Ke Li, et al.Lung Cancer (Amsterdam, Netherlands)|June 5, 2003
P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21Li Su, Yang Sai, Rong Fan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2019
First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor ActivityHui K Gan, Michael Millward, Ye Hua, et al.Bioorganic & Medicinal Chemistry Letters|June 14, 2005
Structure-activity relationships of 1,3,5-triazine-2,4,6-triones as human gonadotropin-releasing hormone receptor antagonistsZhiqiang Guo, Dongpei Wu, Yun-Fei Zhu, et al.Frontiers in Pharmacology|December 2, 2024
Mass balance, metabolism, and pharmacokinetics of [<sup>14</sup>C]amdizalisib, a clinical-stage novel oral selective PI3Kδ inhibitor for the treatment of non-hodgkin's lymphoma, in healthy Chinese volunteersChun-Yang Zhao, Li-Jun Zhang, Chan Sun, et al.Journal of Medicinal Chemistry|August 23, 2014
Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancerHong Jia, Guangxiu Dai, Jianyang Weng, et al.The Journal of Pharmacology and Experimental Therapeutics|November 2, 2023
Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk InhibitorYu Cai, Jianlin He, Zhipeng Wu, et al.Frontiers in Pharmacology|June 13, 2022
Mechanism-Based Pharmacokinetic Model for the Deglycosylation Kinetics of 20(S)-Ginsenosides Rh2Hong-Can Ren, Jian-Guo Sun, Ji-Ye A, et al.Journal of Medicinal Chemistry|October 9, 2007
Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexiaChen Chen, Wanlong Jiang, Fabio Tucci, et al.Pharmacology Research & Perspectives|January 21, 2020
Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitorYu Cai, Jun Yu, Ping Ren, et al.Pageof 4